Jasper Therapeutics falls after $30 mln stock-and-warrants deal

Jasper Therapeutics' JSPR.O shares down 7.3% premarket to $2.40 after follow-on priced

Redwood City, California-based JSPR early Fri announced ~12.3 mln shares, including 675,000 pre-funded warrants, for $30 mln gross proceeds

The offering shares and pre-funded warrants accompanied by warrants to buy up to an additional ~12.3 mln shares

Offering price of $2.43 represents 6.2% discount to stock's last sale of $2.59 on Thurs

Co intends to use net proceeds to advance preclinical/clinical development programs of briquilimab in mast-cell driven diseases, and for other general corp purposes

With ~16.3 mln shares outstanding, JSPR has $42 mln market cap through Thurs

TD Cowen is sole bookrunner for offering

Through Thurs close, JSPR shares had shed ~88% YTD

On Jul 7, shares plunged 55% and closed at $3.04 after co halted its asthma trial for briquilimab due to a drug product lot issue that affected potency

Two days later, JSPR announced a 50% workforce reduction and said it is halting other clinical programs to focus on briquilimab

6 of 10 analysts covering JSPR rate the stock "strong buy" or "buy", rest rate "hold"; median PT is $20, LSEG data reflects